In August 2019, pemigatinib was recognized as an orphan drug in the US to treat myeloid/lymphoid tumors with eosinophilia, PDGFRA, PDGFRB, FGFR1 rearrangement, or PCM1-JAK2. Here, FGFR1 is linked to lymphoid neoplasm.